I used our honeymoon fund to pay for my husband's funeral after he died unexpectedly
Laura Burr had only been married for six months when she held her husband's hand as he died from an undiagnosed heart condition.
Now, the 31-year-old from Oxfordshire is campaigning for health MOTs to be offered from the age of 30 – something she believes could have saved his life.
Currently, free NHS checks are only offered to people aged 40 and over, but Laura says that's too late for many. "If Ed had been tested earlier, even a basic blood pressure or cholesterol check might have given us a warning," she says.
Laura, from Banbury, married her "funny, kind, and chaotic" soulmate Edward in April 2024 in a small ceremony surrounded by loved ones. But, just 186 days later she was holding his hand as doctors turned off his life support machine.
Edward Burr, a 32-year-old primary school teacher, began experiencing flu-like symptoms the day after their wedding. Initially, it seemed like a bad cold.
"He was getting hot and cold sweats, and couldn't sleep,' Laura recalls. 'We thought he just needed rest and vitamin C."
Within weeks, Ed was struggling to breathe. A trip to A&E led to a diagnosis of pneumonia and heart failure – two serious conditions doctors struggled to treat at the same time.
"We were told he'd be easier to treat if it was just one or the other," Laura says. "But because he had both, it was more complicated. They didn't know which was causing the most damage."
Ed spent seven weeks in hospital before being discharged with strict monitoring instructions.
After a brief return home, he was readmitted and fitted with a biventricular assist device (BIVAD) to help his heart pump blood. He was placed on the transplant list – but he never made it to surgery.
If Ed had received a health MOT at 30, even if it didn't save him, I might have had more time with him
In early October, Laura sensed something wasn't right. "The chaplain came to bless him like he always did, but that time I just broke down sobbing," she says.
Just hours later, she got a call to say Ed had taken a turn for the worse. "They told us his BIVAD machine was failing and they couldn't keep him going. I played his favourite music and my sister read him a poem," Laura says. "And then, I held his hand as he died."
Instead of spending their honeymoon fund on a trip to Disneyland the couple had dreamed of, Laura says she used it to pay for his funeral.
Now, Laura is campaigning for change. She's calling for NHS health checks (currently only offered to people aged 40 and over) to be made available from age 30 – a move she believes could save lives.
"If Ed had received a health MOT at 30, even if it didn't save him, I might have had more time with him," she says.
"At his funeral, I kept thinking: how did we get here? We were newlyweds. We should've been arguing over dinner plans, not saying goodbye."
Laura has teamed up with friend Gabriella Evans, who also lost her husband, Tom, 34, to an undiagnosed heart condition. Together, they are campaigning for earlier, routine health screenings including blood pressure and cholesterol checks.
The pair released The Podcast That Shouldn't Exist earlier this month.
In the first episode, Laura told how she walked down the aisle at the wedding and the funeral to the same music, from her husband's favourite film series Lord Of The Rings.
"People in their 30s think they're too young for this stuff," Laura says. "But I'm living proof that you're not."
The check is a free check-up of your overall health and sees everyone aged over 40 assessed for their risk of developing a heart or circulatory condition such as heart disease, kidney disease, type 2 diabetes or stroke in the next 10 years.
Everyone aged 40-74 who does not have a pre-existing condition should be offered the NHS Health Check at least once every five years.
If you have any of the following pre-existing conditions, the NHS says you're not eligible as you should be seen more frequently:
heart disease
chronic kidney disease
diabetes
high blood pressure (hypertension)
atrial fibrillation
transient ischaemic attack
inherited high cholesterol (familial hypercholesterolemia)
heart failure
peripheral arterial disease
stroke
currently being prescribed statins to lower cholesterol
Each year, around 20% of people eligible for one of these checks are invited to come forward, with a view to reach the entire eligible population in a five-year cycle.
Additional reporting by SWNS
Read more about heart health:
4 possible benefits of alcohol as champagne may lower risk of sudden cardiac arrest (Yahoo Life UK, 6-min read)
What to know about common heart defect as Emma Willis undergoes surgery (Yahoo Life UK, 4-min read)
People's heart health in the UK declining rapidly in 'worrying trend (PA Media, 3-min read)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Vaccine against gonorrhoea to roll out in Scotland
A new vaccine against gonorrhoea will be rolled out in Scotland in August following a UK-wide rise in cases. The illness, which is the second most common sexually transmitted infection (STI) in Scotland is potentially painful and in rare cases can be life-threatening. Scottish cases have risen in recent years, with 5,999 infections in 2023 - a rise of 59% from before the Covid pandemic. Those eligible for the vaccine will include gay and bisexual men at highest risk of infection, as well those involved in selling or exchanging sex, regardless of their gender. Syphilis and drug-resistant gonorrhoea increasing World-first gonorrhoea vaccine launched by NHS England as infections soar Doctors and charities call for gonorrhoea vaccine roll-out Those most affected by gonorrhoea in the UK are those aged 16 to 25, gay and bisexual men, and those of black and Caribbean ancestry. The vaccine, which is 30-40% effective, is also being delivered in England and Northern Ireland. Doctors and charities called for vaccinations earlier this year after the UK's Joint Committee on Vaccination and Immunisation (JCVI) recommended a targeted roll-out in November 2023. The Scottish government is funding the vaccination programme north of the border. Public Health Minister Jenny Minto said the campaign was "urgent and timely since the number of diagnoses has been high and the disease is becoming increasingly difficult to treat with antibiotics". She added: "The science tells us that this vaccine will potentially protect thousands of people and prevent the spread of infection. "Anything which stops people from contracting gonorrhoea in the first place can have huge benefits, including ensuring our health system remains resilient by reducing the amount of treatment needed." Dr Sam Ghebrehewet, head of the vaccination and immunisation division at Public Health Scotland, said the jab was a "welcome new intervention". He said: "This vaccination programme is expected to help control and prevent the spread of gonorrhoea. "Public Health Scotland is working with the Scottish government and colleagues across NHS boards to finalise plans for the rollout of this targeted vaccination, offering to those at increased risk of gonorrhoea from August 2025." The vaccine was not designed for gonorrhoea - it is the meningitis B vaccine currently given to babies. The bacteria that cause the two diseases are so closely related that the MenB jab appears to cut gonorrhoea cases by around a third. However, it will not eliminate the risk of catching gonorrhoea - it is normally caught while having sex without a condom. Prof Andrew Pollard, the chair of the JCVI which recommended the vaccine, said despite it only being 30% effective, it was "worth having" and could have "a huge impact" overall. Gonorrhoea is also becoming increasingly difficult to treat. Most cases are treated with a single dose of antibiotics, but there is an 80-year history of the bacterium which causes gonorrhoea repeatedly evolving resistance to antibiotics. This is also happening to current treatments and is why some doctors are concerned gonorrhoea could one day become untreatable. They say the best way to deal with a drug-resistant infection is to never catch it in the first place.
Yahoo
9 hours ago
- Yahoo
World-first blood cancer therapy to be given on NHS
A "Trojan horse" therapy that sneaks toxic drugs inside cancer cells is being made available on the NHS in England in a world first. It can halt the blood cancer myeloma for nearly three times longer than current therapies. The drug is an advanced form of chemotherapy that hits cancer with a bigger dose, while reducing side-effects. Paul Silvester, one of the first people to get it, says the therapy has been "life-changing" and he's now planning history-themed adventures. Myeloma – also known as multiple myeloma – affects part of the immune system called plasma cells. These are made in the spongey bone marrow in the centre of our bones. Paul, who is 60 and from Sheffield, was diagnosed nearly two years ago after the cancer led to broken bones in his back. He had a bone marrow transplant last year, but relapsed around Christmas. He has since been on the new therapy – called belantamab mafodotin – as part of an early access scheme. Within weeks he was in remission. Other treatments could have left him isolating in his bedroom for months, so Paul says the therapy "is absolutely life-changing" and was "creating that opportunity to enjoy" life. Visiting Hadrian's Wall is next on the agenda for history buff Paul; and he's looking forward to one of his daughters graduating later this year. "Most people say 'you look really really well'... I have a good normal life," he told the BBC. Paul's therapy - belantamab mafodotin – is a lethal chemotherapy drug that has been bound to an antibody, similar to the ones the body uses to fight infection. However, these antibodies have been designed to spot markings on the outside of plasma cells. So they travel to cancerous cells, stick to the surface and are then absorbed. Once inside they release their toxic payload, to kill the cancer. The therapy is named Trojan horse therapy after the siege of the city of Troy in Greek mythology, when a giant wooden horse was used to smuggle soldiers into the city. Myeloma cannot be cured, but clinical trials last year showed the Trojan horse therapy halted the cancer for three years, compared to 13 months with current therapies. Prof Peter Johnson, the national clinical director for cancer at NHS England, said the difference was "life-changing". He told me: "This is a really important development for people with myeloma, because although we may not be able to cure the illness, giving them time free of the disease and free of the symptoms is really important. "We've seen in the last few years that using antibodies to deliver chemotherapy drugs directly into cells can make a big difference for a variety of different types of cancer." Around 33,000 people are living with myeloma in the UK. The new drug will be used when the first-choice therapy fails, so around 1,500 patients a year could benefit. The decision comes after a review by the National Institute of Health and Care Excellence (NICE) concluded the drug was cost-effective for NHS use. NICE recommendations are normally adopted in England, Wales and Northern Ireland while Scotland has its own process. The therapy is kinder than other cancer treatments, but is not free from side-effects. After a cancer cell has been destroyed, the remaining chemotherapy drug will leak into the body. This can cause dry eyes and blurred vision. The technical name for these drugs is an antibody-drug-conjugate. This therapy was developed by GSK in the UK with early research taking place in Stevenage and the first clinical trials in London. Prof Martin Kaiser, team leader in myeloma molecular therapy at the Institute of Cancer Research, said these "are very smart drugs" and the difference in side effects compared to other drugs "is really remarkable". While myeloma is still considered an incurable cancer, Prof Kaiser says drugs like this are "an important step towards a functional cure" and he thinks long-term remission will go "above 50% in the next five years". Antibody drug conjugates are being developed for a range of cancers. The limitation is being able to design an antibody that can target the cancer alone. There is one that can target some types of breast cancer. Research is already taking place on stomach and bowel cancer. Shelagh McKinlay, from the charity Myeloma UK, said the approval would "transform the lives of thousands" and it was "fantastic to see the UK at the forefront of myeloma treatment". Health Minister Karin Smyth, said: "This ground-breaking therapy puts the NHS at the forefront of cancer innovation." Exercise improves colon cancer survival, major study shows Breakthrough cancer drug doubles survival in trial
Yahoo
9 hours ago
- Yahoo
‘Trojan horse' treatment given green light for NHS use
Blood cancer patients in England will be among the first in the world to have access to a new 'Trojan horse' treatment, health officials have announced. The targeted therapy can stop myeloma from progressing by nearly three times as long as existing treatments, studies suggest. It is estimated that around 1,500 patients a year with multiple myeloma – an incurable cancer of the bone marrow – will benefit from the treatment. It comes after the National Institute for Health and Care Excellence (Nice) approved belantamab mafodotin, also known as Blenrep and made by GlaxoSmithKline, for NHS use. NHS England said that it is the first health system in the world to roll out the treatment. Officials said that the drug can now be offered to patients whose cancer has progressed or not responded to another first-line treatment. The treatment, which is given as an infusion every three weeks along with other cancer drugs, is a type of antibody drug which targets and attaches to cancer cells. It has been dubbed a 'Trojan horse' treatment because it works by being taken into a cancer cell, before releasing a high concentration of a lethal molecule to destroy the cell from inside. 'Myeloma is an aggressive type of blood cancer, but we have seen a steady improvement in the outlook for patients over recent years as we have introduced new targeted therapies,' Professor Peter Johnson, NHS England's national clinical director for cancer, said. 'I am delighted that patients in England will be the first to benefit from this new treatment, which has the potential to keep cancer at bay for years longer, giving people the chance of more precious time with friends and family. 'This treatment could be life-changing for many patients and their families, and that's why it is so important that the NHS continues to secure quick access to the latest, innovative treatments like this, at affordable prices to the taxpayer.' 🚨 Do you know the key symptoms of #myeloma? 🚨 Help us spread the word by sharing this post! Early diagnosis makes all the difference. If something feels off, don't wait – talk to your GP!#BloodCancerAwarenessMonth @MyelomaUK — DKMS UK | We Delete Blood Cancer (@DKMS_uk) September 6, 2024 Helen Knight, director of medicines evaluation at Nice, said: 'We're delighted that people in the UK will become among the first in the world to access belantamab mafodotin for this indication. 'This recommendation demonstrates our commitment to getting the best care to patients fast, while ensuring value for the taxpayer.' Trials have suggested that the treatment, in combination with bortezomib and dexamethasone, delayed progression of the disease by an average of three years, compared to just over a year for patients taking commonly-used drug daratumumab along with the other treatments. Patient Paul Silvester, 60, from Sheffield, was diagnosed with myeloma in July 2023 and received treatment at the Royal Hallamshire Hospital. The first treatment he was given failed to stop his cancer from progressing so he was given belantamab mafodotin through an early access programme. 'I feel like this treatment has brought the party balloons back in the house. It has been amazing – within the first two or three weeks, after the first dose, I was in remission,' he said. 'It gives me quite a lot of confidence in the drugs and it makes me more optimistic about the future. 'I've been feeling well and I'm still quite active – that's what's important in terms of your quality of life. 'One of my daughters is graduating from university in October and it's a goal for me to be there.' Shelagh McKinlay, director of research and advocacy at blood cancer charity Myeloma UK, said: 'It's fantastic to see the UK at the forefront of myeloma treatment. 'We have been working very hard for the last year to get this treatment approved and we know it will transform the lives of thousands of people with myeloma.' Health Minister Karin Smyth said: 'This groundbreaking therapy puts the NHS at the forefront of cancer innovation. 'By harnessing cutting-edge 'trojan horse' technology, we're offering new hope to blood cancer patients across the country.'
